The Hospital Acquired Pneumonia (HAP) drugs in development market research report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hospital Acquired Pneumonia (HAP). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued products.
GlobalData tracks 45 drugs in development for Hospital Acquired Pneumonia (HAP) by 40 companies/universities/institutes. The top development phase for Hospital Acquired Pneumonia (HAP) is preclinical with ten drugs in that stage. The Hospital Acquired Pneumonia (HAP) pipeline has 45 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hospital Acquired Pneumonia (HAP) pipeline products market are: Helperby Therapeutics Group, Sumitomo Pharma and Glox Therapeutics.
The key targets in the Hospital Acquired Pneumonia (HAP) pipeline products market include Beta Lactamase, Penicillin Binding Protein, and Penicillin Binding Protein 3.
The key mechanisms of action in the Hospital Acquired Pneumonia (HAP) pipeline product include Beta Lactamase Inhibitor with ten drugs in Pre-Registration. The Hospital Acquired Pneumonia (HAP) pipeline products include eight routes of administration with the top ROA being Intravenous and nine key molecule types in the Hospital Acquired Pneumonia (HAP) pipeline products market including Small Molecule, and Biologic.
Hospital Acquired Pneumonia (HAP) overview
Hospital-acquired pneumonia (HAP) is defined as pneumonia acquired during a hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache, and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis, and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.
For a complete picture of Hospital Acquired Pneumonia (HAP)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
